Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats

[1]  N. Ali,et al.  Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model , 2022, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[2]  M. Moran,et al.  Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes , 2022, Nature Communications.

[3]  O. Cortés,et al.  Systematic review and meta-analysis of clinical trials , 2021, Medicine.

[4]  Xiang Cheng,et al.  Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway , 2021, Frontiers in Pharmacology.

[5]  A. Alanazi,et al.  Protective effect of valsartan against doxorubicin‐induced cardiotoxicity: Histopathology and metabolomics in vivo study , 2021, Journal of biochemical and molecular toxicology.

[6]  C. Passino,et al.  Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure , 2021, Critical reviews in clinical laboratory sciences.

[7]  A. Matsuzawa,et al.  Mechanisms of gefitinib-induced interstitial pneumonitis: why and how the TKI perturbs innate immune systems? , 2021, Oncotarget.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  S. Kusumoto,et al.  Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury , 2021, International journal of molecular sciences.

[10]  Gi-Wook Hwang,et al.  Gefitinib initiates sterile inflammation by promoting IL-1β and HMGB1 release via two distinct mechanisms , 2021, Cell death & disease.

[11]  N. Ali,et al.  Role of carnitine in regulation of blood pressure (MAP/SBP) and gene expression of cardiac hypertrophy markers (α/β‐MHC) during insulin‐induced hypoglycaemia: Role of oxidative stress , 2020, Clinical and experimental pharmacology & physiology.

[12]  Qinfu Wang,et al.  Protective effects of valsartan administration on doxorubicin-induced myocardial injury in rats and the role of oxidative stress and NOX2/NOX4 signaling , 2020, Molecular medicine reports.

[13]  M. Schaalan,et al.  A novel protective role of sacubitril/valsartan in cyclophosphamide induced lung injury in rats: impact of miRNA-150-3p on NF-κB/MAPK signaling trajectories , 2020, Scientific Reports.

[14]  Wenbin Dong,et al.  The Changes of Twist1 Pathway in Pulmonary Microvascular Permeability in a Newborn Rat Model of Hyperoxia-Induced Acute Lung Injury , 2020, Frontiers in Pediatrics.

[15]  F. Pinguet,et al.  FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management , 2019, Biomolecules.

[16]  I. Gavras,et al.  Renin–Angiotensin Inhibition in Combating Malignancy: A Review , 2019, AntiCancer Research.

[17]  A. Shimizu,et al.  Molecular hydrogen attenuates gefitinib-induced exacerbation of naphthalene-evoked acute lung injury through a reduction in oxidative stress and inflammation , 2019, Laboratory Investigation.

[18]  R. Shah,et al.  Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology , 2019, Drug Safety.

[19]  N. Câmara,et al.  Butyrate Attenuates Lung Inflammation by Negatively Modulating Th9 Cells , 2019, Front. Immunol..

[20]  A. Keszei,et al.  Serum phosphate and phosphate-regulatory hormones in COPD patients , 2018, Respiratory Research.

[21]  Pengchi Deng,et al.  Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment , 2018, Cell Death Discovery.

[22]  M. A. Ansari,et al.  Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways , 2018, Pharmacological reports : PR.

[23]  A. Hemmati,et al.  Valsartan attenuates bleomycin-induced pulmonary fibrosis by inhibition of NF-κB expression and regulation of Th1/Th2 cytokines , 2018, Immunopharmacology and immunotoxicology.

[24]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[25]  Yawei Xu,et al.  Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents. , 2017, Molecular medicine reports.

[26]  Val Gebski,et al.  Risk of Treatment‐Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta‐analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR‐Mutated Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Thomas J. Smith,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Wang,et al.  The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[29]  R. Shah.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas , 2016, Drug Safety.

[30]  Jie He,et al.  Epidemiology of Lung Cancer. , 2016, Surgical oncology clinics of North America.

[31]  Dongsheng Hong,et al.  Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer , 2016, Medicine.

[32]  Wei Chen,et al.  Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC , 2016, Scientific Reports.

[33]  Dong-Wan Kim,et al.  Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[34]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[35]  Y. Lee,et al.  Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to sarcoidosis: A meta-analysis , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[36]  Yang Yao,et al.  Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials , 2015, Journal of chemotherapy.

[37]  Huidong Shi,et al.  Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. , 2014, Immunity.

[38]  Michael Emmett,et al.  Acetaminophen toxicity and 5-oxoproline (pyroglutamic acid): a tale of two cycles, one an ATP-depleting futile cycle and the other a useful cycle. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[39]  L. Tong,et al.  Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. , 2013, Lung cancer.

[40]  T. Mitsudomi,et al.  Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). , 2013, Japanese journal of clinical oncology.

[41]  Meiman Hong,et al.  Valsartan attenuates oxidative stress and NF-κB activation and reduces myocardial apoptosis after ischemia and reperfusion. , 2013, European journal of pharmacology.

[42]  T. Asano,et al.  Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice , 2013, Adipocyte.

[43]  M. Humbert,et al.  Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[44]  A. Kawada,et al.  Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. , 2012, Japanese journal of clinical oncology.

[45]  O. Matsuno,et al.  Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches , 2012, Respiratory Research.

[46]  Yi‐Gang Li,et al.  Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction , 2012, Journal of cellular and molecular medicine.

[47]  J. Meléndez-Zajgla,et al.  Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis , 2011, European Respiratory Journal.

[48]  M. Raizada,et al.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[49]  S. Keller,et al.  Valsartan Protects Pancreatic Islets and Adipose Tissue From the Inflammatory and Metabolic Consequences of a High-Fat Diet in Mice , 2010, Hypertension.

[50]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[51]  C. Appleyard,et al.  An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis , 2008, Regulatory Peptides.

[52]  D. Jonkers,et al.  Review article: the role of butyrate on colonic function , 2007, Alimentary pharmacology & therapeutics.

[53]  Y. Kondoh,et al.  Interstitial lung disease associated with gefitinib. , 2006, Respiratory medicine.

[54]  C. Ferrario.  Role of Angiotensin II in Cardiovascular Disease — Therapeutic Implications of More Than a Century of Research , 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[55]  K. Uematsu,et al.  Gefitinib‐induced lung injury successfully treated with high‐dose corticosteroids , 2006, Respirology.

[56]  K. Matsuo,et al.  Interstitial Lung Disease in Japanese Patients With Non‐Small Cell Lung Cancer Receiving Gefitinib: An Analysis of Risk Factors and Treatment Outcomes in Okayama Lung Cancer Study Group , 2005, Cancer journal.

[57]  K. Kuwano,et al.  Understanding the mechanisms of drug-associated interstitial lung disease , 2004, British Journal of Cancer.

[58]  Masatsugu Horiuchi.  [Angiotensin II receptor]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[59]  R. Marshall.  The pulmonary renin-angiotensin system. , 2003, Current pharmaceutical design.

[60]  M. Ebina,et al.  Severe acute interstitial pneumonia and gefitinib , 2003, The Lancet.

[61]  N. Koyama,et al.  Enhanced production of IL‐18 in butyrate‐treated intestinal epithelium by stimulation of the proximal promoter region , 2002, European journal of immunology.

[62]  A. Wolff.  Systemic therapy , 2001, Current opinion in oncology.

[63]  A Kahn,et al.  Interstitial lung disease. , 1982, The Journal of the Arkansas Medical Society.

[64]  A. Moncion,et al.  Metabolic consequences of pyruvate kinase inhibition by oxalate in intact rat hepatocytes. , 1981, Biochimie.